Page 1, 2, 3
Notes
57. Lengyel S, Katona E, Zatik J, et al. The impact of serum homocysteine on intima-media thickness in normotensive, white-coat and sustained hypertensive adolescents. Blood Press. 2012;21(1):39–44.
58. Bogdanski P, Miller-Kasprzak E, Pupek-Musialik D, et al. Plasma total homocysteine is a determinant of carotid intima-media thickness and circulating endothelial profenitor cells in patients with newly diagnosed hypertension. Clin Chem Lab Med. 2012;50(6):1107–1113.
59. Johnston, Jernberg, Lagerqvist, et al. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. Am J Cardiol. 2006;97:640–645.
60. Haung, Mai, Liu, et al The oxidation ratio of LDL: A predictor for coronary artery disease. Dis Markers. 2008;24:341–349.
61. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen and cardiovascular disease prediction. N Eng J Med. 2012;367(14)1310–1320.
62. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604.
63. Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for martrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001 Nov. 2;276(44):41279–41287.
64. Podrez, Schmidt, Hoff, et al Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547–1560.
65. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263:256–273.
66. Undurti A, Huang Y, Lupica JA, Smith JD, Didonato JA, Hazen SL. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem. 2009;284:30825–30835.
67. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–2767.
68. Annema W, Nijstad N, Tolle M, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospho- lipase A(2). J Lipid Res. 2010;51:743–754.
69. Malle E, Waeg G, Schreiber R, Gröne EF, Sattler W, Gröne H-J. Immunohistochemical evidence for the myeloper-oxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem. 2000;267:4495–4503.
70. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121:110–122.
71. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001;103:2283–2288.
72. Smith JD. Myeloperoxidase, inflammation and dysfunctional high-density lipoprotein. J Clin Lipidol. 2010;4;382–388.
73. DeSouza CA, Shapiro LF, et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation. 2000.
74. Rahman ST, Merchant N, Haque T, et al. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension : results from the QUALITY study. J Cardiovasc Pharmacol Ther. 2012;17:139.
75. Miyamoto M, Kotani K, Ishibashi S, Taniguchi N. The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients. Int J Vasc Med. 2012. doi:10.1155/2012/453264.
76. Webb CM, Ghatei MA. 17beta-estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation. 2000.
77. Thompson LP, Pinkas G, Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilitation. Circulation. 2000.
78. Fukui M, Kitagawa Y, Ose H, et al. Role of endogenous androgen against insulin resistance and atherosclerosis in men with type 2 diabetes. Curr Diabetes Rev. 2007;3:25–31.
79. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. The omega 3 fatty acid docosahexanoate reduces cytokine induced expression of proathergenic and proinflammatory proteins in human endothelial cells, Arterioscler Thromb. 1994 Nov;14(11)1829–1836.
80. De Caterina R, Liao JK. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000.
81. Farmer A, Montori V, Dinneen S, et al. Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2001;(3):CD003205.
82. Baik I, Abbott RD, Curb JD, et al. Intake of fish and n-3 fatty acids and future risk of metabolic syndrome. J Am Diet Assoc. 2010;110(7):1018–1026.
83. Jacob S, Ruus P, Hermann R, et al, Oral administration of RAC-α-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999.
84. Khanna S, Roy S, et al, Cytokine-induced glucose uptake in skeletal muscle:redox regulation and the role of α-lipoic acid. Am J Physiol. 1999.
85. Ast J, Jablecka A, Bogdanski P, et al. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med Sci Monit. 2010;16(5):CR266–CR271.
86. Bode-Boger SM, Muke J, Surdacki A, et al. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med. 2003;8(2):77–81.
87. Guttman H, Zimllchman R, Boaz M, et al. Effect of long-term L-arginine supplementation on arterial compliance and metabolic parameters in patients with multiple cardiovascular risk factors: randomized, placebo-controlled study. J Cardiovasc Pharmacol. 2010.
88. Lerman A, Burnett JC Jr, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998.
89. Boger RH, Bode-Boger SM, Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation. 1997.
90. Wang BY, Ho HK, Lin PS, et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation. 1999.
91. Schulman SP, Becker LC. L-arginine therapy in acute myocardial infarction: VINTAGE MI randomized clinical trial. JAMA. 2006.
92. Fitzpatrick DF, Bling B, Maggi DA, et al. Vasodilating procyanidins derived from grape seeds. Ann N Y Acad Sci. 2002;957:78–89.
93. Kalin R, Righi A, DelRosso A, Bagchi D, et al. Activin, a grape seed derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. Free Radic Res. 2002;36(8):819–825.
94. Sivaprakasapillai B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism. 2009 Dec;58(12):1743–1746. Epub 2009 Jul 15.
95. Arora R, Basu N, Kapoor V, et al. Anti-inflammatory studies on Curcuma longa (turmeric). Indian J Med Res. 1971;59:1289–1295.
96. Srivastava R. Inhibition of neutrophil response by curcumin. Agents Actions. 1989;28:298–303.
97. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, et al. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis. 1999;147:371–378.
98. Kodai S, Takemura S, Minamiyama Y, et al. S-allyl cysteine prevents CCl(4)-induced acute liver injury in rats. Free Radic Res. 2007.
99. Kim KM, Chun SB, Koo MS, et al. Differential regulation of NO availability from macrophages and endothelial cells by the garlic component S-allyl cysteine. Free Radic Biol Med. 2001.
100. Budoff M. Aged garlic extract retards progression of coronary artery calcification. J Nutr. 2006;136(3 Suppl):741S–744S.
101. Efendy JL, Simmons DL, Campbell GR, Campbell JH. The effect of the aged garlic extract, ‘Kyolic' on the development of experimental atherosclerosis. Atherosclerosis. 1997;132:37–42.
102. Steiner M, Li W. Aged garlic extract, a modulator of cardiovascular risk factors: a dose-finding study on the effects of AGE on platelet functions. J Nutr. 2001;131:980S–984S.
103. Weiss N, Ide N, Abahji T, et al. Aged garlic extract improves homocysteine-induced endothelial dysfunction in macro- and microcirculation. J Nutr. 2006;136(3 Suppl):750S–754S.
104. Williams MJ, Sutherland WH, McCormick MP, et al. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res. 2005;19(4):314–319.
105. Morihara N, Hayama M, Full H. Aged garlic extract scavenges superoxide radicals. Plant Foods Hum Nutr. 2011;66(1):17–21.
106. Reid K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomized controlled trial. Maturitas. 2010;67(2):144–150.
107. Budoff MJ, Takasu J, Flores FR, et al. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. Prev Med. 2004;39(5).
108. Affuso, Mercurio, Fazio, et al Cardiovascular and metabolic effects of berberine. World J Cardiol. 2010 April 26;2(4):71–77.
109. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. January 2001;37(1):117–123.
110. Gao L, Mao Q, Cao J, et al. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221(2):311–316.
111. Rosenfeldt F, Hilton D, Pepe S, et al. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 2003;18(1–4):91–100.
112. Fremont L. Biological effects of resveratrol. Life Sci. 2000;66(8):663–673.
113. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev. 2004;22(3):169–188.
114. Sadruddin S, Arora R. Resveratrol: biologic and therapeutic implications. J Cardiometab Syndr. 2009 Spring;4(2):102–106. Review.
115. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106(13):1652–1658.
116. Ozkanlar S, Akcay F. Antioxidant vitamins in atherosclerosis – animal experiments and clinical studies. Adv Clin Exp Med. 2012 Jan–Feb;21(1):115–123.
117. Enstrom JE, Kanim LE, Breslow L. The relationship between vitamin C intake, general health practices, and mortality in Alameda County, California. Am J Public Health. 1986;76:1124–1130.
118. Cavallaro, Ainis, Bottari, et al. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res. 2003;52:555–562.
119. Kohnen S, Franck T, Van Antwerpen P, et al. Resveratrol inhibits the activity of equine neutrophil myeloperoxidase by a direct interaction with the enzyme. J Agric Food Chem. 2007;55:8080–8087.
120. Pincemail J, Deby C, Thirion A, de Bruyn-Dister M, Goutier R. Human myeloperoxidase activity is inhibited in vitro by quercetin. Comparison with three related compounds. Experientia. 1988 May 15;44(5):450–453.
121. Shiba Y, Kinoshita T, Chuman H, et al. Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites. Chem Res Toxicol. 2008 Aug;21(8):1600–1609.
122. Schewe T, Sies H. Myeloperoxidase-induced lipid peroxidation of LDL in the presence of nitrite. Protection by cocoa flavanols. Biofactors. 2005;24(1–4):49–58.
122. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea. JAMA. 1953;152:1090–1093.
 Dr. Gary Huber is president of the LaValle Metabolic Institute. He spent 20 years as an emergency medicine physician before joining Jim LaValle in the practice of integrative medicine at LMI. Dr. Huber is an adjunct professor teaching integrative medicine practice at the University of Cincinnati College of Pharmacy as well as a clinical preceptor for pharmacy students. Dr. Huber also lectures on hormone replacement therapies and integrative care for the American Academy of Anti-Aging Medicine for the University of South Florida. He has developed the Metabolic Code Professional Weight Loss Program that has proved very beneficial in reversing metabolic syndrome issues. Dr. Huber has a long held interest in nutrition and human physiology as it relates to wellness and longevity. He has served as medical director for the Flying Pig Marathon and is presently on the board of directors for Loveland's Amazing Race, a local charity event.
Page 1, 2, 3 |
